Gene · 8607
NIH grants1,304
NIH grants whose papers are about the gene, through NIH's grant-paper links.
381 to 400 of 1,304
Download this page as JSON| Grant | Title | RUVBL1 papers | Newest fiscal year |
|---|---|---|---|
| F31AI154796 | Defining the regulation of mitochondrial bioenergetics during virus infection | 1 | 2022 |
| F31GM136187 | Supplement Characterizing the mechanism of the INO80 family chromatin remodeling machine | 1 | 2022 |
| F32CA250240 | Defining IKZF1/IKAROS as an oncogene and therapeutic target in MLL-r AML | 1 | 2022 |
| F32GM137463 | Molecular mechanisms of the ACF chromatin remodeling complex | 1 | 2022 |
| K00CA212225 | The Role of USP22 in Prostate Cancer Development and Progression | 1 | 2022 |
| K00CA245732 | Uncovering actionable signaling pathways required for solid tumor brain metastasis | 1 | 2022 |
| K01AG057862 | Synaptic mechanisms of tau-mediated pathogenesis in human iPSC-derived neurons | 1 | 2022 |
| K01AR070895 | Transcriptional Regulatory Complexes in Epidermal Differentiation | 1 | 2022 |
| K08CA230220 | Targeting casein kinase 1-alpha for cancer therapy | 1 | 2022 |
| K99CA255936 | Mechanisms of translational output control in pancreatic cancer | 1 | 2022 |
| P01AG031862 | Epigenetics of Aging and Age-Associated Diseases | 1 | 2022 |
| P01CA129243 | Targets for Therapy for Carcinomas of the Lung | 1 | 2022 |
| P30DK079307 | Pittsburgh Center for Kidney Research | 1 | 2022 |
| P50CA140388 | Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPORE | 1 | 2022 |
| R01AI140705 | SFTSV nonstructural protein NSs-mediated immunopathogenesis | 1 | 2022 |
| R01AI140718 | Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKV | 1 | 2022 |
| R01AI143381 | Regulation of HIV Latency by Host Cell Transcriptional and Epigenetic Networks | 1 | 2022 |
| R01AR062547 | Regulation of the Melanocyte Lineage by the AP2 Transcription Factor Family | 1 | 2022 |
| R01CA122677 | Regulation of Nuclear Signaling Pathways by the Adenovirus E4-ORF3 Protein | 1 | 2022 |
| R01CA176745 | Targeting DOT1L for Degradation in MLL-rearranged Leukemia | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8607/grants?page=20